QUARTERLY REPORT

Q2 2023 — Quarterly report

Q2 2023PDF · 29 pages226 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________
Form 10-Q
__________________________________________________________
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
Commission File Number: 1-10864
__________________________________________________________
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
__________________________________________________________
Delaware 41-1321939
(State or other jurisdiction of
incorporation or organization) (I.R.S. Employer
Identification No.)
UnitedHealth Group Center
55343
9900 Bren Road East
Minnetonka, Minnesota
(Address of principal executive offices) (Zip Code)
(952) 936-1300
(Registrant’s telephone number, including area code)
_________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $.01 par value UNH New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐
Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of July 31, 2023, there were 926,305,139 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.

-- 1 of 29 --

UNITEDHEALTH GROUP
Table of Contents
Page
Part I. Financial Information
Item 1. Financial Statements (unaudited) ......................................................................................................................... 1
Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022 ..................................... 1
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2023 and
2022 ................................................................................................................................................................. 2
Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June
30, 2023 and 2022............................................................................................................................................. 3
Condensed Consolidated Statements of Changes in Equity for the Three and Six Months Ended June 30,
2023 and 2022................................................................................................................................................... 4
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2023 and 2022 .......... 6
Notes to the Condensed Consolidated Financial Statements................................................................................ 7
1. Basis of Presentation.................................................................................................................................... 7
2. Investments ................................................................................................................................................. 8
3. Fair Value .................................................................................................................................................... 10
4. Medical Costs Payable................................................................................................................................. 11
5. Short-Term Borrowings and Long-Term Debt............................................................................................ 11
6. Dividends ..................................................................................................................................................... 12
7. Commitments and Contingencies ................................................................................................................ 12
8. Business Combinations................................................................................................................................ 13
9. Segment Financial Information ................................................................................................................... 14
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations .............................. 16
Item 3. Quantitative and Qualitative Disclosures About Market Risk ............................................................................. 24
Item 4. Controls and Procedures....................................................................................................................................... 24
Part II. Other Information
Item 1. Legal Proceedings ................................................................................................................................................ 24
Item 1A. Risk Factors .......................................................................................................................................................... 24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.............................................................................. 25
Item 5. Other Information................................................................................................................................................. 25
Item 6. Exhibits................................................................................................................................................................. 26
Signatures............................................................................................................................................................................... 27

-- 2 of 29 --

PART I
ITEM 1. FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data) June 30,
2023 December 31,
2022
Assets
Current assets:
Cash and cash equivalents ...................................................................................................................... $ 41,813 $ 23,365
Short-term investments........................................................................................................................... 4,466 4,546
Accounts receivable, net......................................................................................................................... 17,952 17,681
Other current receivables, net................................................................................................................. 16,131 12,769
Assets under management ...................................................................................................................... 3,623 4,087
Prepaid expenses and other current assets.............................................................................................. 5,884 6,621
Total current assets ......................................................................................................................................... 89,869 69,069
Long-term investments................................................................................................................................... 45,988 43,728
Property, equipment and capitalized software, net......................................................................................... 10,926 10,128
Goodwill ......................................................................................................................................................... 101,669 93,352
Other intangible assets, net............................................................................................................................. 15,643 14,401
Other assets..................................................................................................................................................... 16,069 15,027
Total assets .................................................................................................................................................... $ 280,164 $ 245,705
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable............................................................................................................................. $ 31,947 $ 29,056
Accounts payable and accrued liabilities................................................................................................ 29,516 27,715
Short-term borrowings and current maturities of long-term debt........................................................... 6,321 3,110
Unearned revenues ................................................................................................................................. 14,852 3,075
Other current liabilities........................................................................................................................... 30,345 26,281
Total current liabilities.................................................................................................................................... 112,981 89,237
Long-term debt, less current maturities.......................................................................................................... 59,268 54,513
Deferred income taxes .................................................................................................................................... 2,498 2,769
Other liabilities ............................................................................................................................................... 13,261 12,839
Total liabilities................................................................................................................................................ 188,008 159,358
Commitments and contingencies (Note 7)
Redeemable noncontrolling interests.............................................................................................................. 4,788 4,897
Equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding................... — —
Common stock, $0.01 par value - 3,000 shares authorized; 927 and 934 issued and outstanding......... 9 9
Retained earnings ................................................................................................................................... 89,994 86,156
Accumulated other comprehensive loss ................................................................................................. (7,650) (8,393)
Nonredeemable noncontrolling interests ................................................................................................ 5,015 3,678
Total equity..................................................................................................................................................... 87,368 81,450
Total liabilities, redeemable noncontrolling interests and equity ............................................................ $ 280,164 $ 245,705
See Notes to the Condensed Consolidated Financial Statements
1

-- 3 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended
June 30, Six Months Ended
June 30,
(in millions, except per share data) 2023 2022 2023 2022
Revenues:
Premiums............................................................................................................................ $ 72,474 $ 63,896 $ 145,260 $ 127,966
Products.............................................................................................................................. 10,651 9,496 20,918 18,836
Services .............................................................................................................................. 8,663 6,645 16,743 13,017
Investment and other income ............................................................................................. 1,115 295 1,913 662
Total revenues ............................................................................................................................ 92,903 80,332 184,834 160,481
Operating costs:
Medical costs...................................................................................................................... 60,268 52,093 120,113 104,616
Operating costs................................................................................................................... 13,809 11,709 27,434 23,110
Cost of products sold.......................................................................................................... 9,748 8,596 19,153 17,083
Depreciation and amortization ........................................................................................... 1,021 802 1,991 1,590
Total operating costs .................................................................................................................. 84,846 73,200 168,691 146,399
Earnings from operations........................................................................................................ 8,057 7,132 16,143 14,082
Interest expense .......................................................................................................................... (828) (467) (1,582) (900)
Earnings before income taxes.................................................................................................. 7,229 6,665 14,561 13,182
Provision for income taxes......................................................................................................... (1,572) (1,466) (3,130) (2,835)
Net earnings .............................................................................................................................. 5,657 5,199 11,431 10,347
Earnings attributable to noncontrolling interests ....................................................................... (183) (129) (346) (250)
Net earnings attributable to UnitedHealth Group common shareholders ......................... $ 5,474 $ 5,070 11,085 $ 10,097
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic................................................................................................................................... $ 5.89 $ 5.41 $ 11.91 $ 10.75
Diluted................................................................................................................................ $ 5.82 $ 5.34 $ 11.77 $ 10.61
Basic weighted-average number of common shares outstanding ........................................ 930 937 931 939
Dilutive effect of common share equivalents ......................................................................... 10 13 11 13
Diluted weighted-average number of common shares outstanding..................................... 940 950 942 952
Anti-dilutive shares excluded from the calculation of dilutive effect of common share
equivalents.............................................................................................................................. 7 3 6 3
See Notes to the Condensed Consolidated Financial Statements
2

-- 4 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended
June 30, Six Months Ended
June 30,
(in millions) 2023 2022 2023 2022
Net earnings ............................................................................................................... $ 5,657 $ 5,199 $ 11,431 $ 10,347
Other comprehensive (loss) income:
Gross unrealized (losses) gains on investment securities during the period........ (431) (1,331) 209 (3,354)
Income tax effect.................................................................................................. 99 304 (48) 769
Total unrealized (losses) gains, net of tax ....................................................... (332) (1,027) 161 (2,585)
Gross reclassification adjustment for net realized gains included in net
earnings ............................................................................................................ (47) (1) (34) (4)
Income tax effect.................................................................................................. 11 — 8 1
Total reclassification adjustment, net of tax.................................................... (36) (1) (26) (3)
Total foreign currency translation gains (losses) ................................................. 267 (676) 608 242
Other comprehensive (loss) income.......................................................................... (101) (1,704) 743 (2,346)
Comprehensive income............................................................................................... 5,556 3,495 12,174 8,001
Comprehensive income attributable to noncontrolling interests................................. (183) (129) (346) (250)
Comprehensive income attributable to UnitedHealth Group common
shareholders ........................................................................................................... $ 5,373 $ 3,366 $ 11,828 $ 7,751
See Notes to the Condensed Consolidated Financial Statements
3

-- 5 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common Stock
Additional
Paid-In
Capital Retained
Earnings
Accumulated Other
Comprehensive
(Loss) Income
Nonredeemable
Noncontrolling
Interests Total
Equity
Three months ended June 30,
(in millions) Shares Amount
Net Unrealized
(Losses) Gains
on Investments
Foreign
Currency
Translation
(Losses) Gains
Balance at March 31, 2023.............. 932 $ 9 $ — $ 88,852 $ (2,275) $ (5,274) $ 4,509 $ 85,821
Net earnings..................................... 5,474 139 5,613
Other comprehensive (loss) income (368) 267 (101)
Issuances of common stock, and
related tax effects ........................ 1 — 218 218
Share-based compensation .............. 232 232
Common share repurchases............. (6) — (442) (2,585) (3,027)
Cash dividends paid on common
shares ($1.88 per share)............... (1,747) (1,747)
Redeemable noncontrolling
interests fair value and other
adjustments.................................. (8) (8)
Acquisition and other adjustments
of nonredeemable noncontrolling
interests........................................ 478 478
Distribution to nonredeemable
noncontrolling interests............... (111) (111)
Balance at June 30, 2023................. 927 $ 9 $ — $ 89,994 $ (2,643) $ (5,007) $ 5,015 $ 87,368
Balance at March 31, 2022.............. 939 $ 10 $ — $ 78,782 $ (1,137) $ (4,889) $ 3,362 $ 76,128
Net earnings..................................... 5,070 94 5,164
Other comprehensive loss ............... (1,028) (676) (1,704)
Issuances of common stock, and
related tax effects ........................ 1 — 174 174
Share-based compensation .............. 194 194
Common share repurchases............. (5) — (733) (1,767) (2,500)
Cash dividends paid on common
shares ($1.65 per share)............... (1,545) (1,545)
Redeemable noncontrolling
interests fair value and other
adjustments.................................. 365 365
Acquisition and other adjustments
of nonredeemable noncontrolling
interests........................................ 12 12
Distribution to nonredeemable
noncontrolling interests............... (83) (83)
Balance at June 30, 2022................. 935 $ 10 $ — $ 80,540 $ (2,165) $ (5,565) $ 3,385 $ 76,205
See Notes to the Condensed Consolidated Financial Statements
4

-- 6 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common Stock
Additional
Paid-In
Capital Retained
Earnings
Accumulated Other
Comprehensive
(Loss) Income
Nonredeemable
Noncontrolling
Interests Total
Equity
Six months ended March 31,
(in millions) Shares Amount
Net Unrealized
(Losses) Gains
on Investments
Foreign
Currency
Translation
(Losses) Gains
Balance at January 1, 2023.............. 934 $ 9 $ — $ 86,156 $ (2,778) $ (5,615) $ 3,678 $ 81,450
Net earnings..................................... 11,085 252 11,337
Other comprehensive income.......... 135 608 743
Issuances of common stock, and
related tax effects ........................ 3 — 568 568
Share-based compensation .............. 598 598
Common share repurchases............. (10) — (1,075) (3,963) (5,038)
Cash dividends paid on common
shares ($3.53 per share)............... (3,284) (3,284)
Redeemable noncontrolling
interests fair value and other
adjustments.................................. (91) (91)
Acquisition and other adjustments
of nonredeemable noncontrolling
interests........................................ 1,297 1,297
Distribution to nonredeemable
noncontrolling interests............... (212) (212)
Balance at June 30, 2023................. 927 $ 9 $ — $ 89,994 $ (2,643) $ (5,007) $ 5,015 $ 87,368
Balance at January 1, 2022.............. 941 $ 10 $ — $ 77,134 $ 423 $ (5,807) $ 3,285 $ 75,045
Net earnings..................................... 10,097 182 10,279
Other comprehensive (loss) income (2,588) 242 (2,346)
Issuances of common stock, and
related tax effects ........................ 4 — 507 507
Share-based compensation .............. 476 476
Common share repurchases............. (10) — (1,217) (3,783) (5,000)
Cash dividends paid on common
shares ($3.10 per share)............... (2,908) (2,908)
Redeemable noncontrolling
interests fair value and other
adjustments.................................. 234 234
Acquisition and other adjustments
of nonredeemable noncontrolling
interests........................................ 103 103
Distribution to nonredeemable
noncontrolling interests............... (185) (185)
Balance at June 30, 2022................. 935 $ 10 $ — $ 80,540 $ (2,165) $ (5,565) $ 3,385 $ 76,205
See Notes to the Condensed Consolidated Financial Statements
5

-- 7 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Six Months Ended
June 30,
(in millions) 2023 2022
Operating activities
Net earnings.............................................................................................................................................................. $ 11,431 $ 10,347
Noncash items:
Depreciation and amortization ......................................................................................................................... 1,991 1,590
Deferred income taxes...................................................................................................................................... (482) (15)
Share-based compensation ............................................................................................................................... 604 504
Other, net.......................................................................................................................................................... (91) 215
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
Accounts receivable ......................................................................................................................................... 197 (4,204)
Other assets ...................................................................................................................................................... (2,001) (643)
Medical costs payable ...................................................................................................................................... 2,408 4,029
Accounts payable and other liabilities ............................................................................................................. 1,547 807
Unearned revenues ........................................................................................................................................... 11,755 (440)
Cash flows from operating activities........................................................................................................................ 27,359 12,190
Investing activities
Purchases of investments ......................................................................................................................................... (9,225) (8,903)
Sales of investments................................................................................................................................................. 3,188 2,348
Maturities of investments......................................................................................................................................... 4,463 3,189
Cash paid for acquisitions, net of cash assumed ...................................................................................................... (8,161) (7,150)
Purchases of property, equipment and capitalized software .................................................................................... (1,589) (1,212)
Other, net.................................................................................................................................................................. (424) (532)
Cash flows used for investing activities................................................................................................................... (11,748) (12,260)
Financing activities
Common share repurchases...................................................................................................................................... (5,000) (5,000)
Cash dividends paid ................................................................................................................................................. (3,284) (2,908)
Proceeds from common stock issuances .................................................................................................................. 628 756
Repayments of long-term debt ................................................................................................................................. (2,125) (1,100)
Proceeds from short-term borrowings, net............................................................................................................... 3,426 1,340
Proceeds from issuance of long-term debt ............................................................................................................... 6,394 5,922
Customer funds administered................................................................................................................................... 4,069 5,786
Other, net.................................................................................................................................................................. (1,377) (1,546)
Cash flows from financing activities........................................................................................................................ 2,731 3,250
Effect of exchange rate changes on cash and cash equivalents................................................................................ 106 57
Increase in cash and cash equivalents .................................................................................................................. 18,448 3,237
Cash and cash equivalents, beginning of period.................................................................................................. 23,365 21,375
Cash and cash equivalents, end of period ............................................................................................................ $ 41,813 $ 24,612
See Notes to the Condensed Consolidated Financial Statements
6

-- 8 of 29 --

UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”)
is a health care and well-being company with a mission to help people live healthier lives and help make the health system work
better for everyone. Our two distinct, yet complementary business platforms — Optum and UnitedHealthcare — are working to
help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the
individuals and organizations the Company is privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted
Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end
condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures
required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the
Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual
audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read
together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and
Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the
SEC (2022 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments
necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and
judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and
goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve
matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is
included in earnings in the period in which the estimate is adjusted.
Revenues - Products and Services
As of June 30, 2023 and December 31, 2022, accounts receivable related to products and services were $7.7 billion and
$7.1 billion, respectively. As of June 30, 2023, revenue expected to be recognized in any future year related to remaining
performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less,
contracts where revenue recognized as invoiced and contracts with variable consideration related to undelivered performance
obligations, was $12.2 billion, of which approximately half is expected to be recognized in the next three years.
7

-- 9 of 29 --

2. Investments
A summary of debt securities by major security type is as follows:
(in millions) Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses Fair
Value
June 30, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations.................... $ 4,990 $ — $ (283) $ 4,707
State and municipal obligations .................................. 7,334 10 (427) 6,917
Corporate obligations .................................................. 23,582 11 (1,643) 21,950
U.S. agency mortgage-backed securities .................... 8,504 5 (799) 7,710
Non-U.S. agency mortgage-backed securities ............ 3,148 — (304) 2,844
Total debt securities - available-for-sale ............................ 47,558 26 (3,456) 44,128
Debt securities - held-to-maturity:
U.S. government and agency obligations.................... 466 — (11) 455
State and municipal obligations .................................. 28 — (3) 25
Corporate obligations .................................................. 246 — — 246
Total debt securities - held-to-maturity............................... 740 — (14) 726
Total debt securities............................................................ $ 48,298 $ 26 $ (3,470) $ 44,854
December 31, 2022
Debt securities - available-for-sale:
U.S. government and agency obligations.................... $ 4,093 $ 1 $ (285) $ 3,809
State and municipal obligations .................................. 7,702 25 (479) 7,248
Corporate obligations .................................................. 23,675 17 (1,798) 21,894
U.S. agency mortgage-backed securities .................... 7,379 15 (808) 6,586
Non-U.S. agency mortgage-backed securities ............ 3,077 1 (294) 2,784
Total debt securities - available-for-sale ............................ 45,926 59 (3,664) 42,321
Debt securities - held-to-maturity:
U.S. government and agency obligations.................... 578 — (14) 564
State and municipal obligations .................................. 29 — (3) 26
Corporate obligations .................................................. 89 — — 89
Total debt securities - held-to-maturity .............................. 696 — (17) 679
Total debt securities............................................................ $ 46,622 $ 59 $ (3,681) $ 43,000
The Company held $4.2 billion and $3.7 billion of equity securities as of June 30, 2023 and December 31, 2022, respectively.
The Company’s investments in equity securities primarily consist of employee savings plan related investments, venture
investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair values. Additionally,
the Company’s investments included $1.4 billion and $1.5 billion of equity method investments in operating businesses in the
health care sector as of June 30, 2023 and December 31, 2022, respectively. The allowance for credit losses on held-to-maturity
securities at June 30, 2023 and December 31, 2022 was not material.
8

-- 10 of 29 --

The amortized cost and fair value of debt securities as of June 30, 2023, by contractual maturity, were as follows:
Available-for-Sale Held-to-Maturity
(in millions) Amortized
Cost Fair
Value Amortized
Cost Fair
Value
Due in one year or less........................................................................................ $ 4,646 $ 4,613 $ 466 $ 461
Due after one year through five years................................................................. 14,748 13,935 225 219
Due after five years through ten years................................................................ 11,332 10,206 31 30
Due after ten years .............................................................................................. 5,180 4,820 18 16
U.S. agency mortgage-backed securities ............................................................ 8,504 7,710 — —
Non-U.S. agency mortgage-backed securities.................................................... 3,148 2,844 — —
Total debt securities............................................................................................ $ 47,558 $ 44,128 $ 740 $ 726
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that
individual securities have been in a continuous unrealized loss position were as follows:
Less Than 12 Months 12 Months or Greater Total
(in millions) Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses
June 30, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations... $ 2,300 $ (28) $ 1,902 $ (255) $ 4,202 $ (283)
State and municipal obligations ................. 2,769 (46) 3,324 (381) 6,093 (427)
Corporate obligations ................................. 6,346 (122) 13,974 (1,521) 20,320 (1,643)
U.S. agency mortgage-backed securities.... 3,111 (79) 4,314 (720) 7,425 (799)
Non-U.S. agency mortgage-backed
securities ............................................... 577 (15) 2,239 (289) 2,816 (304)
Total debt securities - available-for-sale ........... $ 15,103 $ (290) $ 25,753 $ (3,166) $ 40,856 $ (3,456)
December 31, 2022
Debt securities - available-for-sale:
U.S. government and agency obligations... $ 2,007 $ (96) $ 1,290 $ (189) $ 3,297 $ (285)
State and municipal obligations ................. 4,630 (288) 1,178 (191) 5,808 (479)
Corporate obligations ................................. 13,003 (893) 6,637 (905) 19,640 (1,798)
U.S. agency mortgage-backed securities.... 3,561 (345) 2,239 (463) 5,800 (808)
Non-U.S. agency mortgage-backed
securities ............................................... 1,698 (128) 976 (166) 2,674 (294)
Total debt securities - available-for-sale ........... $ 24,899 $ (1,750) $ 12,320 $ (1,914) $ 37,219 $ (3,664)
The Company’s unrealized losses from debt securities as of June 30, 2023 were generated from approximately 35,000 positions
out of a total of 41,000 positions. The Company believes that it will timely collect the principal and interest due on its debt
securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate
increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s
assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt
securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company
evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit
deterioration since purchase. As of June 30, 2023, the Company did not have the intent to sell any of the available-for-sale debt
securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit
losses on available-for-sale debt securities at June 30, 2023 and December 31, 2022 was not material.
9

-- 11 of 29 --

3. Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values
disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of
three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy
classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in
Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair
value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair and
Carrying
Value
June 30, 2023
Cash and cash equivalents.................................................................. $ 41,763 $ 50 $ — $ 41,813
Debt securities - available-for-sale:
U.S. government and agency obligations.................................... 4,318 389 — 4,707
State and municipal obligations .................................................. — 6,917 — 6,917
Corporate obligations.................................................................. 36 21,732 182 21,950
U.S. agency mortgage-backed securities .................................... — 7,710 — 7,710
Non-U.S. agency mortgage-backed securities ............................ — 2,844 — 2,844
Total debt securities - available-for-sale ............................................ 4,354 39,592 182 44,128
Equity securities ................................................................................. 2,270 37 70 2,377
Assets under management ................................................................. 1,332 2,190 101 3,623
Total assets at fair value ..................................................................... $ 49,719 $ 41,869 $ 353 $ 91,941
Percentage of total assets at fair value ............................................... 54 % 45 % 1 % 100 %
December 31, 2022
Cash and cash equivalents.................................................................. $ 23,202 $ 163 $ — $ 23,365
Debt securities - available-for-sale:
U.S. government and agency obligations.................................... 3,505 304 — 3,809
State and municipal obligations .................................................. — 7,248 — 7,248
Corporate obligations.................................................................. 7 21,695 192 21,894
U.S. agency mortgage-backed securities .................................... — 6,586 — 6,586
Non-U.S. agency mortgage-backed securities ............................ — 2,784 — 2,784
Total debt securities - available-for-sale ............................................ 3,512 38,617 192 42,321
Equity securities ................................................................................. 2,043 35 70 2,148
Assets under management ................................................................. 1,788 2,203 96 4,087
Total assets at fair value ..................................................................... $ 30,545 $ 41,018 $ 358 $ 71,921
Percentage of total assets at fair value ............................................... 42 % 57 % 1 % 100 %
There were no transfers in or out of Level 3 financial assets or liabilities during the six months ended June 30, 2023 or 2022.
10

-- 12 of 29 --

The following table presents a summary of fair value measurements by level and carrying values for certain financial
instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair
Value
Total
Carrying
Value
June 30, 2023
Debt securities - held-to-maturity............................... $ 651 $ 75 $ — $ 726 $ 740
Long-term debt and other financing obligations ........ $ — $ 58,644 $ — $ 58,644 $ 61,217
December 31, 2022
Debt securities - held-to-maturity............................... $ 577 $ 102 $ — $ 679 $ 696
Long-term debt and other financing obligations ........ $ — $ 53,626 $ — $ 53,626 $ 56,823
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are
subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were
no significant fair value adjustments for these assets and liabilities recorded during the six months ended June 30, 2023 or 2022.
4. Medical Costs Payable
The following table shows the components of the change in medical costs payable for the six months ended June 30:
(in millions) 2023 2022
Medical costs payable, beginning of period....................................................................................... $ 29,056 $ 24,483
Acquisitions........................................................................................................................................ 1 171
Reported medical costs:
Current year................................................................................................................................. 120,773 104,936
Prior years ................................................................................................................................... (660) (320)
Total reported medical costs .............................................................................................................. 120,113 104,616
Medical payments:
Payments for current year ........................................................................................................... (91,621) (78,937)
Payments for prior years ............................................................................................................. (25,602) (21,355)
Total medical payments ..................................................................................................................... (117,223) (100,292)
Medical costs payable, end of period ................................................................................................. $ 31,947 $ 28,978
For the six months ended June 30, 2023 and 2022, prior years’ medical cost reserve development included no individual factors
that were significant. Medical costs payable included reserves for claims incurred by insured customers but not yet reported to
the Company of $22.0 billion and $20.0 billion at June 30, 2023 and December 31, 2022, respectively.
5. Short-Term Borrowings and Long-Term Debt
In March 2023, the Company issued $6.5 billion of senior unsecured notes consisting of the following:
(in millions, except percentages) Par Value
4.250% notes due January 2029 ................................................................................................................. $ 1,250
4.500% notes due April 2033 ..................................................................................................................... 1,500
5.050% notes due April 2053 ..................................................................................................................... 2,000
5.200% notes due April 2063 ..................................................................................................................... 1,750
As of June 30, 2023, the Company had $4.4 billion of commercial paper outstanding, with a weighted-average annual interest
rate of 5.1%.
For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the
Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-
K.
11

-- 13 of 29 --

6. Dividends
In June 2023, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual
rate of $7.52 compared to $6.60 per share, which the Company had paid since June 2022. Declaration and payment of future
quarterly dividends is at the discretion of the Board of Directors and may be adjusted as business needs or market conditions
change.
The following table provides details of the Company’s dividend payments during the six months ended June 30, 2023:
Payment Date Amount per Share Total Amount Paid
(in millions)
March 21 ....................................................................................................... $ 1.65 $ 1,537
June 27 .......................................................................................................... 1.88 1,747
7. Commitments and Contingencies
Pending Acquisitions
As of June 30, 2023, the Company has entered into agreements to acquire companies in the health care sector, subject to
regulatory approval and other customary closing conditions. The total anticipated consideration required for these acquisitions,
excluding the payoff of acquired indebtedness, is approximately $5 billion.
Legal Matters
The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits
brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s
businesses, including management and administration of health benefit plans and other services. These matters include medical
malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits
coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of
costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where
the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present
novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the
early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to
estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be
incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These
include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services
(CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the
Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade
Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the
U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the
Consumer Financial Protection Bureau (CFPB), the Defense Contract Audit Agency and other governmental authorities.
Similarly, our international businesses are also subject to investigations, audits and reviews by applicable foreign governments,
including South American and other non-U.S. governmental authorities. Certain of the Company’s businesses have been
reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements
under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data
validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers
and such audits may result in retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the
Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15,
2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12,
2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved to dismiss
the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the
court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without
prejudice. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.
12

-- 14 of 29 --

8. Business Combinations
During the six months ended June 30, 2023, the Company completed several business combinations for total consideration of
$8.2 billion.
Acquired assets (liabilities) at acquisition date were:
(in millions)
Cash and cash equivalents...................................................................................................................... $ 104
Accounts receivable and other current assets......................................................................................... 550
Property, equipment and other long-term assets .................................................................................... 542
Other intangible assets ........................................................................................................................... 1,795
Total identifiable assets acquired ...................................................................................................... 2,991
Medical costs payable ............................................................................................................................ (1)
Accounts payable and other current liabilities ....................................................................................... (473)
Other long-term liabilities ...................................................................................................................... (617)
Total identifiable liabilities acquired................................................................................................. (1,091)
Total net identifiable assets .......................................................................................................... 1,900
Goodwill................................................................................................................................................. 7,734
Redeemable noncontrolling interests ..................................................................................................... (113)
Nonredeemable noncontrolling interests................................................................................................ (1,297)
Net assets acquired ....................................................................................................................... $ 8,224
The majority of goodwill is not deductible for income tax purposes. The preliminary purchase price allocations for the various
business combinations are subject to adjustment as valuation analyses, primarily related to intangible assets and contingent
liabilities, are finalized.
The acquisition date fair values and weighted-average useful lives assigned to intangible assets were:
(in millions, except years) Fair
Value
Weighted-
Average
Useful Life
Acquired finite-lived intangible assets:
Customer-related.................................................................................................................................. $ 223 12 years
Trademarks and technology................................................................................................................. 171 5 years
Other ..................................................................................................................................................... 38 6 years
Total acquired finite-lived intangible assets............................................................................................. 432 9 years
Total acquired indefinite-lived intangible assets - operating licenses and certificates............................. 1,363
Total acquired intangible assets................................................................................................................ $ 1,795
The results of operations and financial condition of acquired entities have been included in the Company’s consolidated results
and the results of the corresponding operating segment as of the date of acquisition. Through June 30, 2023, acquired entities
impact on revenues and net earnings was not material.
Unaudited pro forma revenues and net earnings for the six months ended June 30, 2023 and 2022, as if the business
combinations had occurred on January 1, 2022, were immaterial for both periods.
13

-- 15 of 29 --

9. Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more
information on the Company’s segments, see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial
Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-K. Total assets at Optum
Health increased to $80.8 billion as of June 30, 2023 compared to $69.0 billion as of December 31, 2022, primarily due to
goodwill from business combinations of $7.0 billion.
The following tables present reportable segment financial information:
Optum
(in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum
Eliminations Optum Corporate and
Eliminations Consolidated
Three Months Ended June 30, 2023
Revenues - unaffiliated customers:
Premiums................................... $ 67,047 $ 5,427 $ — $ — $ — $ 5,427 $ — $ 72,474
Products ..................................... — 51 39 10,561 — 10,651 — 10,651
Services...................................... 2,584 3,541 1,995 543 — 6,079 — 8,663
Total revenues - unaffiliated
customers....................................... 69,631 9,019 2,034 11,104 — 22,157 — 91,788
Total revenues - affiliated customers. — 14,454 2,615 17,496 (893) 33,672 (33,672) —
Investment and other income............. 600 444 25 46 — 515 — 1,115
Total revenues.................................... $ 70,231 $ 23,917 $ 4,674 $ 28,646 $ (893) $ 56,344 $ (33,672) $ 92,903
Earnings from operations................... $ 4,358 $ 1,525 $ 968 $ 1,206 $ — $ 3,699 $ — $ 8,057
Interest expense ................................. — — — — — — (828) (828)
Earnings before income taxes............ $ 4,358 $ 1,525 $ 968 $ 1,206 $ — $ 3,699 $ (828) $ 7,229
Three Months Ended June 30, 2022
Revenues - unaffiliated customers:
Premiums................................... $ 59,368 $ 4,528 $ — $ — $ — $ 4,528 $ — $ 63,896
Products ..................................... — 6 58 9,432 — 9,496 — 9,496
Services...................................... 2,542 2,740 1,034 329 — 4,103 — 6,645
Total revenues - unaffiliated
customers....................................... 61,910 7,274 1,092 9,761 — 18,127 — 80,037
Total revenues - affiliated customers. — 10,224 2,181 15,038 (588) 26,855 (26,855) —
Investment and other income............. 195 85 9 6 — 100 — 295
Total revenues.................................... $ 62,105 $ 17,583 $ 3,282 $ 24,805 $ (588) $ 45,082 $ (26,855) $ 80,332
Earnings from operations................... $ 3,850 $ 1,399 $ 839 $ 1,044 $ — $ 3,282 $ — $ 7,132
Interest expense ................................. — — — — — — (467) (467)
Earnings before income taxes............ $ 3,850 $ 1,399 $ 839 $ 1,044 $ — $ 3,282 $ (467) $ 6,665
14

-- 16 of 29 --

Optum
(in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum
Eliminations Optum Corporate and
Eliminations Consolidated
Six Months Ended June 30, 2023
Revenues - unaffiliated customers:
Premiums................................... $ 134,505 $ 10,755 $ — $ — $ — $ 10,755 $ — $ 145,260
Products..................................... — 95 79 20,744 — 20,918 — 20,918
Services ..................................... 5,139 6,630 3,921 1,053 — 11,604 — 16,743
Total revenues - unaffiliated
customers....................................... 139,644 17,480 4,000 21,797 — 43,277 — 182,921
Total revenues - affiliated customers — 28,720 5,125 34,175 (1,752) 66,268 (66,268) —
Investment and other income ............ 1,055 721 45 92 — 858 — 1,913
Total revenues ................................... $ 140,699 $ 46,921 $ 9,170 $ 56,064 $ (1,752) $ 110,403 $ (66,268) $ 184,834
Earnings from operations .................. $ 8,701 $ 3,301 $ 1,875 $ 2,266 $ — $ 7,442 $ — $ 16,143
Interest expense ................................. — — — — — — (1,582) (1,582)
Earnings before income taxes ........... $ 8,701 $ 3,301 $ 1,875 $ 2,266 $ — $ 7,442 $ (1,582) $ 14,561
Six Months Ended June 30, 2022
Revenues - unaffiliated customers:
Premiums................................... $ 119,305 $ 8,661 $ — $ — $ — $ 8,661 $ — $ 127,966
Products..................................... — 12 98 18,726 — 18,836 — 18,836
Services ..................................... 5,057 5,298 2,008 654 — 7,960 — 13,017
Total revenues - unaffiliated
customers....................................... 124,362 13,971 2,106 19,380 — 35,457 — 159,819
Total revenues - affiliated customers — 20,053 4,319 29,329 (1,141) 52,560 (52,560) —
Investment and other income ............ 338 241 76 7 — 324 — 662
Total revenues ................................... $ 124,700 $ 34,265 $ 6,501 $ 48,716 $ (1,141) $ 88,341 $ (52,560) $ 160,481
Earnings from operations .................. $ 7,648 $ 2,765 $ 1,686 $ 1,983 $ — $ 6,434 $ — $ 14,082
Interest expense ................................. — — — — — — (900) (900)
Earnings before income taxes ........... $ 7,648 $ 2,765 $ 1,686 $ 1,983 $ — $ 6,434 $ (900) $ 13,182
15

-- 17 of 29 --

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and
Notes and with our 2022 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8,
“Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms
“UnitedHealth Group,” the “Company,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of
Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and
Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic
conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and
uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking
statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2022 10-K
and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make
the health system work better for everyone. Our two distinct, yet complementary business platforms — Optum and
UnitedHealthcare — are working to help build a modern, high-performing health system through improved access,
affordability, outcomes and experiences for the individuals and organizations we are privileged to serve.
We have four reportable segments:
• Optum Health;
• Optum Insight;
• Optum Rx; and
• UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement
and UnitedHealthcare Community & State.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” in our 2022 10-K and additional information on our segments
can be found in this Item 2 and in Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item
1 of this report.
Business Trends
Our businesses participate in the United States, South America and certain other international health markets. We expect overall
spending on health care to continue to grow in the future due to inflation, medical technology and pharmaceutical advancement,
regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market
growth may be affected by a variety of factors, including macroeconomic conditions and regulatory changes, which could
impact our results of operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefits, products and services, we start with our view of expected future costs,
including medical cost trends, inflation and labor market dynamics. We frequently evaluate and adjust our approach in each of
the local markets we serve, considering all relevant factors, such as product positioning, price competitiveness and
environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio thresholds and
similar revenue adjustments. We will continue seeking to balance growth and profitability across all these dimensions.
The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect
broad-based competition to continue as the industry adapts to individual and employer needs.
Government programs in the community and senior sector tend to receive lower rates of increase than the commercial market
due to governmental budget pressures and lower cost trends.
16

-- 18 of 29 --

Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs.
During the second quarter, we observed increased care patterns, primarily related to outpatient procedures for seniors, which
may continue in future periods. We endeavor to mitigate those increases by engaging physicians and consumers with
information and helping them make clinically sound choices, with the objective of helping them achieve quality, affordable
care.
Regulatory Trends and Uncertainties
Medicare Advantage Rates. Medicare Advantage rate notices over the years have at times resulted in industry base rates well
below industry forward medical trend. For example, the Final Notice for 2024 rates resulted in an industry base rate decrease,
well short of what is an increasing industry forward medical cost trend, creating continued pressure in the Medicare Advantage
program. Further, substantial revisions to the risk adjustment model, which serves to adjust rates to reflect a patient’s health
status and care resource needs, will result in reduced funding and potentially benefits for people, especially those with some of
the greatest health and social challenges.
As a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures
and reductions for a particular period. For example, we can seek to intensify our medical and operating cost management, make
changes to the size and composition of our care provider networks, adjust member benefits and implement or increase the
member premiums supplementing the monthly payments we receive from the government. Additionally, we decide annually on
a county-by-county basis where we will offer Medicare Advantage plans.
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select second quarter 2023 year-over-year operating comparisons to second quarter 2022 and other
financial results.
• Consolidated revenues grew 16%, UnitedHealthcare revenues grew 13% and Optum revenues grew 25%.
• UnitedHealthcare served 1.6 million more people, driven by growth across our U.S. businesses.
• Consolidated earnings from operations of $8.1 billion compared to $7.1 billion last year, included growth of 13% at both
UnitedHealthcare and Optum.
• Diluted earnings per common share were $5.82.
• Cash flows from operations for the six months ended June 30, 2023 were $27.4 billion.
• Return on equity was 26.8%.
17

-- 19 of 29 --

RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share
data)
Three Months Ended
June 30, Increase/
(Decrease) Six Months Ended
June 30, Increase/
(Decrease)
2023 2022 2023 vs. 2022 2023 2022 2023 vs. 2022
Revenues:
Premiums............................................. $ 72,474 $ 63,896 $ 8,578 13 % $ 145,260 $ 127,966 $ 17,294 14 %
Products............................................... 10,651 9,496 1,155 12 20,918 18,836 2,082 11
Services ............................................... 8,663 6,645 2,018 30 16,743 13,017 3,726 29
Investment and other income .............. 1,115 295 820 278 1,913 662 1,251 189
Total revenues ............................................. 92,903 80,332 12,571 16 184,834 160,481 24,353 15
Operating costs:
Medical costs....................................... 60,268 52,093 8,175 16 120,113 104,616 15,497 15
Operating costs.................................... 13,809 11,709 2,100 18 27,434 23,110 4,324 19
Cost of products sold........................... 9,748 8,596 1,152 13 19,153 17,083 2,070 12
Depreciation and amortization ............ 1,021 802 219 27 1,991 1,590 401 25
Total operating costs ................................... 84,846 73,200 11,646 16 168,691 146,399 22,292 15
Earnings from operations ............................ 8,057 7,132 925 13 16,143 14,082 2,061 15
Interest expense ........................................... (828) (467) (361) 77 (1,582) (900) (682) 76
Earnings before income taxes ..................... 7,229 6,665 564 8 14,561 13,182 1,379 10
Provision for income taxes.......................... (1,572) (1,466) (106) 7 (3,130) (2,835) (295) 10
Net earnings................................................. 5,657 5,199 458 9 11,431 10,347 1,084 10
Earnings attributable to noncontrolling
interests.................................................... (183) (129) (54) 42 (346) (250) (96) 38
Net earnings attributable to UnitedHealth
Group common shareholders .................. $ 5,474 $ 5,070 $ 404 8 % $ 11,085 $ 10,097 $ 988 10 %
Diluted earnings per share attributable to
UnitedHealth Group common
shareholders ............................................ $ 5.82 $ 5.34 $ 0.48 $ 11.77 $ 10.61 $ 1.16
Medical care ratio (a) .................................. 83.2 % 81.5 % 1.7 % 82.7 % 81.8 % 0.9 %
Operating cost ratio ..................................... 14.9 14.6 0.3 14.8 14.4 0.4
Operating margin......................................... 8.7 8.9 (0.2) 8.7 8.8 (0.1)
Tax rate........................................................ 21.7 22.0 (0.3) 21.5 21.5 —
Net earnings margin (b)............................... 5.9 6.3 (0.4) 6.0 6.3 (0.3)
Return on equity (c)..................................... 26.8 % 27.9 % (1.1) % 27.5 % 27.9 % (0.4) %
(a) Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.
(b) Net earnings margin attributable to UnitedHealth Group shareholders.
(c) Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’
equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity
balances at the end of each of the quarters in the year presented.
18

-- 20 of 29 --

2023 RESULTS OF OPERATIONS COMPARED TO 2022 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenues
The increases in revenues were primarily driven by growth in the number of people served through Medicare Advantage and
Medicaid, pricing trends and growth across the Optum businesses. Revenues also increased due to increased investment
income, primarily driven by increased interest rates.
Medical Costs and MCR
Medical costs increased primarily due to growth in people served through Medicare Advantage and Medicaid. The MCR
increased as a result of elevated care activity, primarily relating to outpatient care for seniors, and business mix. For the three
months ended June 30, 2023, the MCR also increased due to decreased favorable reserve development.
Operating Cost Ratio
The operating cost ratio increased primarily due to business mix and investments to support future growth, partially offset by
continued productivity advances.
Reportable Segments
See Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more
information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including people
served by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted
scripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also
allow management and investors to evaluate and understand business mix, including the level and scope of services provided to
people, and pricing trends when comparing the metrics to revenue by segment.
The following table presents a summary of the reportable segment financial information:
Three Months Ended
June 30, Increase/
(Decrease) Six Months Ended
June 30, Increase/
(Decrease)
(in millions, except percentages) 2023 2022 2023 vs. 2022 2023 2022 2023 vs. 2022
Revenues
UnitedHealthcare ......................................... $ 70,231 $ 62,105 $ 8,126 13 % $ 140,699 $ 124,700 $ 15,999 13 %
Optum Health ...................................... 23,917 17,583 6,334 36 46,921 34,265 12,656 37
Optum Insight...................................... 4,674 3,282 1,392 42 9,170 6,501 2,669 41
Optum Rx ............................................ 28,646 24,805 3,841 15 56,064 48,716 7,348 15
Optum eliminations ............................. (893) (588) (305) 52 (1,752) (1,141) (611) 54
Optum .......................................................... 56,344 45,082 11,262 25 110,403 88,341 22,062 25
Eliminations................................................. (33,672) (26,855) (6,817) 25 (66,268) (52,560) (13,708) 26
Consolidated revenues................................. $ 92,903 $ 80,332 $ 12,571 16 % $ 184,834 $ 160,481 $ 24,353 15 %
Earnings from operations
UnitedHealthcare ......................................... $ 4,358 $ 3,850 $ 508 13 % $ 8,701 $ 7,648 $ 1,053 14 %
Optum Health ...................................... 1,525 1,399 126 9 3,301 2,765 536 19
Optum Insight...................................... 968 839 129 15 1,875 1,686 189 11
Optum Rx ............................................ 1,206 1,044 162 16 2,266 1,983 283 14
Optum .......................................................... 3,699 3,282 417 13 7,442 6,434 1,008 16
Consolidated earnings from operations ....... $ 8,057 $ 7,132 $ 925 13 % $ 16,143 $ 14,082 $ 2,061 15 %
Operating margin
UnitedHealthcare ......................................... 6.2 % 6.2 % — % 6.2 % 6.1 % 0.1 %
Optum Health ...................................... 6.4 8.0 (1.6) 7.0 8.1 (1.1)
Optum Insight...................................... 20.7 25.6 (4.9) 20.4 25.9 (5.5)
Optum Rx ............................................ 4.2 4.2 — 4.0 4.1 (0.1)
Optum .......................................................... 6.6 7.3 (0.7) 6.7 7.3 (0.6)
Consolidated operating margin.................... 8.7 % 8.9 % (0.2) % 8.7 % 8.8 % (0.1) %
19

-- 21 of 29 --

UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
Three Months Ended
June 30, Increase/
(Decrease) Six Months Ended
June 30, Increase/
(Decrease)
(in millions, except percentages) 2023 2022 2023 vs. 2022 2023 2022 2023 vs. 2022
UnitedHealthcare Employer & Individual - Domestic ..... $ 16,759 $ 15,567 $ 1,192 8 % $ 33,303 $ 31,389 $ 1,914 6 %
UnitedHealthcare Employer & Individual - Global.......... 2,325 2,247 78 3 4,488 4,380 108 2
UnitedHealthcare Employer & Individual - Total .... 19,084 17,814 1,270 7 37,791 35,769 2,022 6
UnitedHealthcare Medicare & Retirement ....................... 32,440 28,625 3,815 13 65,446 57,725 7,721 13
UnitedHealthcare Community & State ............................. 18,707 15,666 3,041 19 37,462 31,206 6,256 20
Total UnitedHealthcare revenues.............................. $ 70,231 $ 62,105 $ 8,126 13 % $ 140,699 $ 124,700 $ 15,999 13 %
The following table summarizes the number of people served by our UnitedHealthcare businesses, by major market segment
and funding arrangement:
June 30, Increase/(Decrease)
(in thousands, except percentages) 2023 2022 2023 vs. 2022
Commercial - Domestic:
Risk-based .......................................................................................................................... 8,035 8,010 25 — %
Fee-based............................................................................................................................ 19,140 18,480 660 4
Total Commercial - Domestic.......................................................................................... 27,175 26,490 685 3
Medicare Advantage ............................................................................................................. 7,590 6,945 645 9
Medicaid................................................................................................................................ 8,355 7,990 365 5
Medicare Supplement (Standardized) ................................................................................... 4,330 4,355 (25) (1)
Total Community and Senior ........................................................................................... 20,275 19,290 985 5
Total UnitedHealthcare - Domestic Medical ................................................................... 47,450 45,780 1,670 4
Commercial - Global............................................................................................................. 5,385 5,465 (80) (1)
Total UnitedHealthcare - Medical .................................................................................... 52,835 51,245 1,590 3 %
Supplemental Data:
Medicare Part D stand-alone ............................................................................................ 3,355 3,330 25 1 %
UnitedHealthcare’s revenues increased due to growth in the number of people served through individual and group Medicare
Advantage plans; growth in existing Medicaid markets, including a greater mix of people with higher acuity needs; and an
increase in the number of people served through commercial offerings. Earnings from operations increased due to increased
investment income and the factors impacting revenue, partially offset by elevated care activity, primarily relating to outpatient
care for seniors.
Optum
Total revenues and earnings from operations increased due to growth across the Optum businesses. The results by segment
were as follows:
Optum Health
Revenues at Optum Health increased primarily due to organic growth in patients served under value-based care arrangements
and business combinations. Earnings from operations increased due to increased investment income and cost management
initiatives, partially offset by higher senior outpatient and behavioral health care activity and costs associated with serving
newly added patients under value-based care arrangements. Optum Health served approximately 103 million people as of
June 30, 2023 compared to 101 million people as of June 30, 2022.
Optum Insight
Revenues and earnings from operations at Optum Insight increased due to growth in business services as a result of business
combinations and growth in technology services.
20

-- 22 of 29 --

Optum Rx
Revenues and earnings from operations at Optum Rx increased due to growth in specialty pharmacy offerings and higher script
volumes from growth in people served. Earnings from operations also increased as a result of continued supply chain
management initiatives. Optum Rx fulfilled 381 million and 357 million adjusted scripts in the second quarters of 2023 and
2022, respectively.
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
Six Months Ended
June 30, Increase/
(Decrease)
(in millions) 2023 2022 2023 vs. 2022
Sources of cash:
Cash provided by operating activities.......................................................................................... $ 27,359 $ 12,190 $ 15,169
Issuances of short-term borrowings and long-term debt, net of repayments............................... 7,695 6,162 1,533
Proceeds from common stock issuances...................................................................................... 628 756 (128)
Customer funds administered ...................................................................................................... 4,069 5,786 (1,717)
Total sources of cash............................................................................................................................ 39,751 24,894
Uses of cash:
Common stock repurchases ......................................................................................................... (5,000) (5,000) —
Cash paid for acquisitions, net of cash assumed.......................................................................... (8,161) (7,150) (1,011)
Purchases of investments, net of sales and maturities ................................................................ (1,574) (3,366) 1,792
Purchases of property, equipment and capitalized software........................................................ (1,589) (1,212) (377)
Cash dividends paid ..................................................................................................................... (3,284) (2,908) (376)
Other ............................................................................................................................................ (1,801) (2,078) 277
Total uses of cash................................................................................................................................. (21,409) (21,714)
Effect of exchange rate changes on cash and cash equivalents ........................................................... 106 57 49
Net increase in cash and cash equivalents ........................................................................................... $ 18,448 $ 3,237 $ 15,211
2023 Cash Flows Compared to 2022 Cash Flows
Increased cash flows provided by operating activities were primarily driven by an increase in unearned revenue due to the June
receipt of our July CMS premium payment of $11.8 billion and changes in working capital accounts. Other significant changes
in sources or uses of cash year-over-year included increased net issuances of short-term borrowings and long-term debt and
decreased net purchases of investments, partially offset by decreased customer funds administered and increased cash paid for
acquisitions.
Financial Condition
As of June 30, 2023, our cash, cash equivalent, available-for-sale debt securities and equity securities balances of $90.1 billion
included approximately $41.8 billion of cash and cash equivalents (of which $1.2 billion was available for general corporate
use), $44.1 billion of debt securities and $4.2 billion of investments in equity securities. Given the significant portion of our
portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to
have a material impact on our liquidity or capital position. Our available-for-sale debt securities portfolio had a weighted-
average duration of 3.9 years and a weighted-average credit rating of “Double A” as of June 30, 2023. When multiple credit
ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average
credit rating.
21

-- 23 of 29 --

Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital
resources and uses of liquidity are as follows:
Cash Requirements. A summary of our cash requirements as of December 31, 2022 was disclosed in Part II, Item 7,
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2022 10-K. During the six
months ended June 30, 2023, there were no material changes to this previously disclosed information outside the ordinary
course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We
continually evaluate opportunities to expand our operations, including through internal development of new products, programs
and technology applications and business combinations.
Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing
program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for
general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 5 of Notes to the
Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated
Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2022 10-K.
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a defined debt to
debt-plus-shareholders’ equity ratio of not more than 60%. As of June 30, 2023, our debt to debt-plus-shareholders’ equity
ratio, as defined and calculated under the credit facilities, was approximately 40%.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as, to
meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information
on our long-term debt, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of
this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and
Supplementary Data” in our 2022 10-K.
Credit Ratings. Our credit ratings as of June 30, 2023 were as follows:
Moody’s (a) S&P Global Fitch A.M. Best
Ratings Outlook Ratings Outlook Ratings Outlook Ratings Outlook
Senior unsecured debt.......................... A3 Positive A+ Stable A Stable A Stable
Commercial paper................................ P-2 n/a A-1 n/a F1 n/a AMB-1+ n/a
(a) On July 27, 2023, Moody’s upgraded the credit rating on our senior unsecured debt to A2 with an outlook of Stable and the credit rating on our
commercial paper to P-1.
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating
cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic
and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase
the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. During the six months ended June 30, 2023, we repurchased approximately 10 million shares at
an average price of $483.78 per share. As of June 30, 2023, we had Board of Directors’ authorization to purchase up to 21
million shares of our common stock.
Dividends. In June 2023, the Company’s Board of Directors increased our quarterly cash dividend to shareholders to an annual
rate of $7.52 compared to $6.60 per share. For more information on our dividend, see Note 6 of Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1 of this report.
Pending Acquisitions. As of June 30, 2023, we have entered into agreements to acquire companies in the health care sector,
subject to regulatory approval and other customary closing conditions. The total anticipated consideration required for these
acquisitions, excluding the payoff of acquired indebtedness, is approximately $5 billion.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8,
“Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” included in Part II, Item 7 in our 2022 10-K.
RECENTLY ISSUED ACCOUNTING STANDARDS
There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated
Financial Statements.
22

-- 24 of 29 --

CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates,
which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and
estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent
liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends.
On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results,
however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical
accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included
in Part II, Item 7 in our 2022 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the
Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2022 10-
K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements
which are intended to take advantage of the “safe harbor” provisions of the federal securities law. The words “believe,”
“expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify
forward-looking statements. These statements may contain information about financial prospects, economic conditions and
trends and involve risks and uncertainties. Actual results could differ materially from those that management expects,
depending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs;
new or changes in existing health care laws or regulations, or their enforcement or application; reductions in revenue or delays
to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of
risk adjustment data validation audits; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to
maintain and achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information
systems or if our technology products do not operate as intended; cyberattacks, other privacy/data security incidents, or our
failure to comply with related regulations; risks and uncertainties associated with our businesses providing pharmacy care
services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to our
public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and
maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of
potential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government
investigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risks associated with public
health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to
attract, develop, retain, and manage the succession of key employees and executives; our investment portfolio performance;
impairment of our goodwill and intangible assets; failure to protect proprietary rights to our databases, software and related
products; downgrades in our credit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from
external financings to fund our obligations, maintain our debt to total capital ratio at targeted levels, maintain our quarterly
dividend payment cycle, or continue repurchasing shares of our common stock.
This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial
condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K.
By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks,
uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations
expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-
looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-
looking statements, except as required by law.
23

-- 25 of 29 --

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt
across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of
interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in
comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1%
point or 2% points as of June 30, 2023 on our investment income and interest expense per annum, and the fair value of our
investments and debt (in millions, except percentages):
June 30, 2023
Increase (Decrease) in Market Interest Rate
Investment
Income Per
Annum
Interest
Expense Per
Annum Fair Value of
Financial Assets Fair Value of
Financial Liabilities
2 %................................................................................... $ 1,025 $ 469 $ (3,500) $ (8,164)
1........................................................................................ 512 234 (1,799) (4,458)
(1) ..................................................................................... (512) (207) 1,882 5,415
(2) ..................................................................................... (1,025) (410) 3,817 12,059
Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on
the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.
ITEM 4. CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in
reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time
periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the
participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our
disclosure controls and procedures as of June 30, 2023. Based upon that evaluation, our Chief Executive Officer and Chief
Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of
June 30, 2023.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2023 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1 of this report.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item
1A, “Risk Factors” of our 2022 10-K, which could materially affect our business, financial condition or future results. The risks
described in our 2022 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that
we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2022 10-K.
24

-- 26 of 29 --

ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities (a)
Second Quarter 2023
For the Month Ended Total Number of
Shares Purchased Average Price Paid
Per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
Maximum Number of
Shares That May Yet Be
Purchased Under The
Plans or Programs
(in millions) (in millions) (in millions)
April 30, 2023.................................. 1.2 $ 499.99 1.2 25.8
May 31, 2023................................... 1.5 486.68 1.5 24.3
June 30, 2023................................... 3.5 475.99 3.5 20.8
Total................................................. 6.2 $ 483.07 6.2
(a) In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In June 2018, the
Board of Directors renewed our share repurchase program with an authorization to repurchase up to 100 million shares of our common stock in open
market purchases or other types of transactions (including prepaid or structured repurchase programs). There is no established expiration date for the
program.
ITEM 5. OTHER INFORMATION
Trading Arrangements
During the quarter ended June 30, 2023, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under the
Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities
intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1
trading arrangement.
25

-- 27 of 29 --

ITEM 6. EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company
files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the
Securities Exchange Act of 1934 under Commission File No. 1-10864.
3.1 Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the
Company’s Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2 Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated
by reference to Exhibit 3.2 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on
February 26, 2021)
4.1 Amended and Restated Indenture, dated as of April 27, 2023, between UnitedHealth Group Incorporated and
Wilmington Trust Company, as successor trustee (incorporated by reference to Exhibit 4.1 to UnitedHealth
Group Incorporated’s Current Report on Form 8-K filed on April 28, 2023)
4.2 Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National
Association (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3,
SEC File Number 333-149031, filed on February 4, 2008)
4.3 Supplemental Indenture, dated as of April 18, 2023, between UnitedHealth Group Incorporated and U.S. Bank
Trust Company, National Association, as trustee, relating to the 6.875% Senior Notes due 2038 (incorporated
by reference to Exhibit 4.1 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on April
24, 2023)
31.1 Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its
XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document.
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
________________
* Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The
Company will furnish copies thereof to the SEC upon request.
26

-- 28 of 29 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
UNITEDHEALTH GROUP INCORPORATED
/s/ ANDREW WITTY Chief Executive Officer
(principal executive officer)
Dated: August 2, 2023
Andrew Witty
/s/ JOHN REX Executive Vice President and
Chief Financial Officer
(principal financial officer)
Dated: August 2, 2023
John Rex
/s/ THOMAS ROOS Senior Vice President and
Chief Accounting Officer
(principal accounting officer)
Dated: August 2, 2023
Thomas Roos
27

-- 29 of 29 --